Medicenna Reports Positive Voting Results from Shareholder Meeting
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a leading clinical-stage immunotherapy company, recently shared the results of its annual meeting of shareholders. The meeting marked a significant moment for the company as it solidified its board of directors and laid the groundwork for future endeavors.
Board Members Elected at the Meeting
At this year's meeting, Medicenna was pleased to announce that all nominees from the management information provided earlier were successfully elected as directors. Each nominee received overwhelming support from shareholders, demonstrating a strong vote of confidence in the leadership team.
Detailed Vote Results
The voting results revealed substantial backing for the directors:
- Dr. Fahar Merchant: 35,539,547 votes (99.25% for, 0.75% against)
- Mr. Albert Beraldo: 35,572,009 votes (99.35% for, 0.65% against)
- Dr. John (Jack) Geltosky: 35,432,573 votes (98.96% for, 1.04% against)
- Ms. Karen Dawes: 35,574,263 votes (99.35% for, 0.65% against)
- Mr. Karim Lalji: 35,401,699 votes (98.87% for, 1.13% against)
In total, 55.75% of the company's issued and outstanding common shares were represented at the meeting, reflecting strong shareholder engagement and commitment.
Farewell and Gratitude
We acknowledge Dr. John H. Sampson's decision not to stand for re-election but are grateful for his years of service. His transition to a consulting role emphasizes his continuing commitment to Medicenna’s mission. Mr. Albert Beraldo, the Lead Independent Director, expressed appreciation for Dr. Sampson's invaluable contributions, reiterating the board's dedication to achieving Medicenna's strategic objectives.
Future of Medicenna
As a clinical-stage company focused on groundbreaking developments in immunotherapy, Medicenna is poised for significant advancements in the field. Their pioneering work includes the development of Superkines, such as MDNA11, a next-generation IL-2, which uniquely enhances the immune response against tumors. Moreover, the company continues to innovate with their IL-4 Empowered Superkine, bizaxofusp, which has already entered several clinical trials, demonstrating promising outcomes for patients with challenging cancers.
Looking Ahead
With a committed board and a solid strategic direction, Medicenna Therapeutics is set to continue on its path of innovation. Shareholders can look forward to upcoming developments and the positive impact of the newly elected board members, who are dedicated to advancing the company’s mission.
Frequently Asked Questions
What were the main outcomes of Medicenna's annual meeting?
Medicenna successfully elected all proposed board nominees, reflecting strong shareholder support.
Who were the key board members elected?
The key elected members included Dr. Fahar Merchant, Mr. Albert Beraldo, Dr. John Geltosky, Ms. Karen Dawes, and Mr. Karim Lalji.
What is the role of Dr. John H. Sampson now?
Dr. Sampson will continue to support Medicenna in a consulting role following his exit from the board.
How many shares were represented at the meeting?
A total of 55.75% of the issued and outstanding common shares were represented during the meeting.
What is 'bizaxofusp' and its significance?
Bizaxofusp is Medicenna's IL-4 Empowered Superkine, currently involved in clinical trials for treating recurrent brain cancer, showcasing the company’s commitment to innovative therapies.
